5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.

Company

Oct. 4

Weekly Loss

Angie's List  (NASDAQ: ANGI  )

$16.70

30%

GTx  (NASDAQ: GTXI  )

$1.67

20%

Arena Pharmaceuticals  (NASDAQ: ARNA  )

$4.84

16%

Diamond Foods (NASDAQ: DMND  )

$20.86

14%

J.C. Penney  (NYSE: JCP  )

$7.86

13%

Source: Barron's.

Let's start with Angie's List, the premium online website operator that offers vetted service reviews. The company confirmed last week that it's testing a new $10 annual membership in some key markets. That's a 75% discount to its current $40 rate. 

The Wall Street Journal went on to report that the $10 offers reverted back to $40, but the damage has been done. Fears that Angie's List memberships are sliding -- forcing Angie's List to this dramatic test -- are scaring away investors.  

GTx slipped after informing its workforce on Tuesday that 60% of them will be let go. The biotech was pounded this summer after a failed late-stage drug trial for GTX-024, GTx's lead candidate that aimed to prevent the wasting away of muscle mass for lung cancer patients. GTx is still gunning for approval overseas, but it will have to do so with 53 fewer non-executive employees.

Arena Pharmaceuticals lost some weight after a pair of unflattering analyst moves. First it was Credit Suisse slashing its price target on the obesity drug market from $5 to $4. Then Cowen initiated coverage with a ho-hum "market perform" rating. Credit Suisse analyst Lee Kalowski sees soft sales for Arena's Belviq after analyzing three months of prescription data.

Diamond Foods more than reversed the prior week's 10% gain after posting disappointing quarterly results. Earnings did clock in ahead of expectations, but it was the weak guidance that led investors to cash out of the salty-snacks giant. 

It certainly seemed as if the company behind Kettle Brand potato chips, Emerald nuts, and Pop Secret microwaveable popcorn was positioned well after an upgrade from BB&T Capital Markets just days before the earnings release. It didn't pan out that way.

Finally we have J.C. Penney falling to levels last seen in 1982, as the department-store chain received yet another analyst downgrade. This time it was Maxim Group reacting to the retailer's slippery financials. Raising funds in a desperate stock offering also didn't impress Fitch, which lowered its credit rating on J.C. Penney.

Ready for a bounce
If you owned some of these losers, how about following the smart money into some high-yielding winners? Dividend stocks can make you rich. It's as simple as that. While they don't garner the notability of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 06, 2013, at 8:41 AM, RSRdriver wrote:

    Just think! Arena still has Swiss rejection (when that happens the many countries that use Swiss drug standards are out too!), The UE surely to laugh at Belviq once more at a future date, Sub $5 stock ownership bias bylaws at the institutions and funds, the DTC ad campaign failure,

    and the usual various Areniac conspiracies and secret Wall Street attacks to deal with! Not to mention,the likely publishing by some MD group or association of their rejection of this "marginal" and over priced drug!

    This has to have been and remain one of the best short plays of all time!!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2670041, ~/Articles/ArticleHandler.aspx, 9/18/2014 3:50:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement